Cancel
BenchSci
BenchSci Employees
15 people indexed:
-
1ukg9@yqf9wytq.l70 Sign up to see email
-
qp112@ftw4gwy8.8f6 Sign up to see email
-
86fl@1u6aj2j2.0la Sign up to see email
-
0j2549y4@t82ty954.t5q Sign up to see email
-
y3gu@tq9q03vl.0xl Sign up to see email
-
y608r@0t6t04dy.j9p Sign up to see email
-
ykpy@jf207vf8.91w Sign up to see email
-
3qtxw@qpj0g4wj.d83 Sign up to see email
-
v2wkk@u9vzqq6f.96z Sign up to see email
-
42fd4zu@urur2q1d.u60 Sign up to see email
-
kx12tapy@3uw93v1d.6z2 Sign up to see email
-
9z3q@t0d831zv.g9j Sign up to see email
-
2pqy8jq@3vyk5zgg.qjl Sign up to see email
-
ur0@qxj6yy3g.u9p Sign up to see email
-
37k@193v4xlu.uqu Sign up to see email
BenchSci Company Information
BenchSci has developed ASCEND, a GenAI platform aimed at accelerating drug discovery and enhancing complex research workflows across various therapeutic areas. ASCEND harnesses the power of a multi-modal AI evidence engine, which is constructed using ontologies to interpret biomedical experiments effectively. This platform is distinctive for its ability to analyze experiments by understanding both textual and visual data, making it a biology-specific multimodal AI tool. BenchSci provides access to an extensive range of biomedical data, including closed access papers, patents, preprints, and third-party data, ensuring a robust foundation for research and development. Additionally, the company offers scalable enterprise-grade software solutions tailored for workflows that were previously unmapped, integrating internal pharmaceutical data with high-grade security across all therapeutic areas. The innovation and potential of ASCEND have been recognized in its recent raise of $95 million in Series D funding, which underscores its role in fostering drug discovery innovation.
Report inaccurate information
Report inaccurate information
